Francesca Sangalli

Francesca Sangalli

Auto-generated profile, based on publicly available information

Francesca Sangalli

Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2015 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
MRM Radaelli
M Radaelli
LML Moiola
L Moiola
FSF Sangalli
F Sangalli
FEFederica Esposito
Federica Esposito
VBV Barcella
V Barcella
GCG Comi
G Comi
Objective: To assess the long-term benefit-risk profile of repeated courses of rituximab in Caucasian patients affected by neuromyelitis optica (NMO) and related disorders, in everyday clinical practice. Methods: This is a prospective observational study performed at San Raffaele Hospital, Milan, Italy. From February 2006, we recruited 21 patients affected by NMO and NMO spectrum of disorders (NMOSD) whom underwent at least one cycle of intravenous (i.v.) rituximab and then were followed for at least 2 years. Results: At a mean follow-up time of 48 months, we observed a significant reduction of the annualized relapse rate (ARR), from 2.0 to 0.16 ( p < 0.01); and of the median Expanded Disability Status Scale (EDSS), from 5.5 to 4.0 ( p < 0.013). There were 12 patients (57%) who remained disease free during the follow-up period. Five patients (24%) reported mild hematological adverse events. Serious infectious adverse events were reported by another four patients: These were all wheelchair bound at the beginning of their rituximab treatment. Conclusions: A fixed treatment scheme of rituximab, with re-treatment every 6 months, was efficacious for NMO and NMOSD, with a good safety profile; however, to obtain an even better benefit-risk ratio, close monitoring of CD19+ B cells should be performed before the re-treatment of patients with high-level disability, concomitant leukopenia and hypogammaglobulinemia.

12 February 2019 in Neurology
Verified
Journal Article
Open access
PDF file
GCGloria Dalla Costa
Gloria Dalla Costa
VMVittorio Martinelli
Vittorio Martinelli
FSFrancesca Sangalli
Francesca Sangalli
LMLucia Moiola
Lucia Moiola
BCBruno Colombo
Bruno Colombo
GCGiancarlo Comi
Giancarlo Comi
Objective To assess the prognostic role of serum neurofilament light chains (NfL) for clinically defined multiple sclerosis (CDMS) and McDonald 2017 multiple sclerosis (MS) in patients with clinically isolated syndromes (CIS). Methods We retrospectively analyzed data of patients admitted to our neurologic department between 2000 and 2015 for a first demyelinating event. We evaluated baseline serum NfL in addition to CSF, MRI, and clinical data. Results Among 222 patients who were enrolled (mean follow-up 100.6 months), 45 patients (20%) developed CDMS and 141 patients (63.5%) developed 2017 MS at 2 years. Serum NfL (median 22.0, interquartile range 11.6–40.4 pg/mL) was noticeably increased in patients with a recent relapse, with a high number of T2 and gadolinium-enhancing lesions at baseline MRI. Serum NfL was prognostic for both CDMS and McDonald 2017 MS, with a threefold and a twofold respective reduction in CDMS and 2017 MS risk in those patients with low and extremely low levels of NfL. The results remained unchanged subsequent to adjustment for such established MS prognostic factors as oligoclonal bands, Gd-enhancing lesions, and a high T2 lesion load at baseline MRI. NfL was associated with disability at baseline but not at follow-up. Conclusions Serum NfL have a prognostic value for CIS patient conversion to MS. NfL might play a twin role as biomarker in MS as peak level measurements can act as a quantitative marker of serious inflammatory activity, while steady-state levels can be a reflection of neurodegenerative and chronic inflammatory processes.

1 May 2017 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PDF file
SSSundararajan Srinivasan
Sundararajan Srinivasan
MDMarco Di Dario
Marco Di Dario
ARAlessandra Russo
Alessandra Russo
RMRamesh Menon
Ramesh Menon
EBElena Brini
Elena Brini
CFCinthia Farina
Cinthia Farina
Objective: To perform systematic transcriptomic analysis of multiple sclerosis (MS) risk genes in peripheral blood mononuclear cells (PBMCs) of subjects with distinct MS stages and describe the pathways characterized by dysregulated gene expressions. Methods: We monitored gene expression levels in PBMCs from 3 independent cohorts for a total of 297 cases (including clinically isolated syndromes (CIS), relapsing-remitting MS, primary and secondary progressive MS) and 96 healthy controls by distinct microarray platforms and quantitative PCR. Differential expression and pathway analyses for distinct MS stages were defined and validated by literature mining. Results: Genes located in the vicinity of MS risk variants displayed altered expression in peripheral blood at distinct stages of MS compared with the healthy population. The frequency of dysregulation was significantly higher than expected in CIS and progressive forms of MS. Pathway analysis for each MS stage–specific gene list showed that dysregulated genes contributed to pathogenic processes with scientific evidence in MS. Conclusions: Systematic gene expression analysis in PBMCs highlighted selective dysregulation of MS susceptibility genes playing a role in novel and well-known pathogenic pathways.

13 February 2019 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
GCGloria Dalla Costa
Gloria Dalla Costa
VMVittorio Martinelli
Vittorio Martinelli
LMLucia Moiola
Lucia Moiola
FSFrancesca Sangalli
Francesca Sangalli
BCBruno Colombo
Bruno Colombo
GCGiancarlo Comi
Giancarlo Comi

11 June 2010 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
FSF. Sangalli
F. Sangalli
LML. Moiola
L. Moiola
SBS. Bucello
S. Bucello
PAP. Annovazzi
P. Annovazzi
ARA. Rizzo
A. Rizzo
GCGiancarlo Comi
Giancarlo Comi

1 December 2017 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
GCGloria Dalla Costa
Gloria Dalla Costa
MRMarta Radaelli
Marta Radaelli
SMSimona Maida
Simona Maida
FSFrancesca Sangalli
Francesca Sangalli
BCBruno Colombo
Bruno Colombo
VMVittorio Martinelli
Vittorio Martinelli